Dr Barry Moore, Xstalbio
Dr Barry Moore
studied at the University of Nottingham gaining a First Class
Honours BSc in Chemistry in 1982.
He carried out his
PhD under the supervision of Prof Jim Turner FRS and Prof Martyn
Poliakoff FRS also at Nottingham developing a time-resolved
infrared spectrometer for study of transient metal carbonyl
species and graduated in 1985.
research with Prof John Osborn, University of Louis Pasteur in
Strasbourg, France and with Prof Chris Lowe at the Institute of
Biotechnology, University of Cambridge he was being appointed to
a Lectureship in Physical Chemistry at Strathclyde in 1990 and
subsequently promoted to Reader.
Moore's research is focused in the areas of biophysical
chemistry and self assembly with particular emphasis on
stabilization and characterization of enzymes under low water
conditions, nanostructured materials, biomolecular imprinting
and the spectroscopy and formulation of biopharmaceuticals.
2005 he and Prof Peter Halling were involved with the successful
bid for the Centre for Excellence in Biocatalysis,
Biotransformations and Biomanufacture (CoEBio3) which has a main
centre at University of Manchester with Satellites in
Strathclyde, Heriot-Watt and York.
recognized the expertise at Strathclyde in biophysical
characterization and optimisation of biocatalysts for use in
invention with Dr MC Parker of a generic self-assembly method
for coating peptides, proteins, nucleic acids, and nanoparticles
onto the surface of water-soluble microcrystals led to the
founding of the spin-out company
XstalBio Ltd (external link) to commercialise the
company specializes in the formulation and delivery of
biopharmaceuticals and is working with major pharmaceutical,
vaccine and biotechnology companies from Europe and the US.
role as Chief Scientist, Dr Moore has directed the research and
development at XstalBio and built up a strong IP portfolio which
includes granted patents in Europe, US, China, India and Japan. XstalBio sponsor a Senior Industrial Fellowship for Dr Moore to
support his work at Strathclyde in the area of Physical Organic
Moore's expertise in biopharmaceutical formulation was
recognized by his election as scientific secretary of the
European Association of Pharma Biotech (EAPB) in 2007 and his
appointment in 2006 as a Chair of the Academy of Pharmaceutical
Sciences Focus Group on Therapeutic Biomolecules and Vaccines.
these roles he has served on the scientific committees of
conferences and workshops held in the UK, Europe and US.